1. Home
  2. CCEL vs GBIO Comparison

CCEL vs GBIO Comparison

Compare CCEL & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cryo-Cell International Inc.

CCEL

Cryo-Cell International Inc.

HOLD

Current Price

$3.38

Market Cap

32.7M

Sector

Health Care

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.34

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCEL
GBIO
Founded
1989
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.7M
36.3M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
CCEL
GBIO
Price
$3.38
$5.34
Analyst Decision
Hold
Buy
Analyst Count
1
5
Target Price
N/A
$8.88
AVG Volume (30 Days)
12.4K
107.9K
Earning Date
02-27-2026
03-12-2026
Dividend Yield
11.87%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,747,500.00
$15,270,000.00
Revenue This Year
$0.30
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.10
$3.00
52 Week High
$8.79
$8.43

Technical Indicators

Market Signals
Indicator
CCEL
GBIO
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
CCEL
GBIO

About CCEL Cryo-Cell International Inc.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: